Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Your trusted source for real-time market insights, expert analysis, and breaking financial news. We deliver actionable updates on global markets, stocks, crypto, and economic trends empowering investors to make informed decisions every day.
Contact us: contact@financeworld-news.com
© Copyright 2025 - financeworld-news.com